Eli Lilly & Co., the Fortune 500 pharma firm that makes the weight-loss injection Zepbound (tirzepetide), has a comparable oral drug in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg in January. told the TV. 13, 2025.
Gam1983/Getty Images
